Home / Resources / Articles (page 30)

Articles

The list of articles below are ordered by most recent. You will find articles here that are also listed in other categories. The list below is a catch-all for all articles on the site.

Social Determinants First: Using CKM and SDOH to Sequence Diabetes Therapies in 2026

Clinician reviewing cardiovascular, kidney, and metabolic risk with social determinants to guide diabetes therapy decisions

A patient’s A1C can look acceptable on paper while everything else is quietly heading in the wrong direction. Cardiovascular risk is rising, kidney function is slipping, and the patient keeps missing follow-up visits because of cost, transportation, or work constraints. Most clinicians have seen this scenario play out, even when …

Read More »

Diabetes Care in the GLP-1 Era: Re-Designing Visits When One Drug Does So Much

Doctor reviewing diabetes metrics with patient during a GLP-1 era clinic visit using digital health tools

GLP-1 receptor agonists have changed diabetes care faster than almost any therapy in recent history. In many ways, one medication now touches glucose control, weight loss, cardiovascular risk, and even liver health. However, while outcomes have evolved, the typical clinic visit has stayed the same. As a result, clinicians often …

Read More »

GLP-1s and Serious Mental Illness: Tackling Antipsychotic-Associated Weight Gain

GLP-1 injection pen and metabolic monitoring tools illustrating treatment for antipsychotic-related weight gain

For many patients, antipsychotic medications are life-changing, even life-saving. Yet the same treatments that stabilize mood and thought can quietly drive weight gain, insulin resistance, and rising cardiometabolic risk. Over time, this unintended consequence places patients with serious mental illness at a much higher risk for obesity, type 2 diabetes, …

Read More »

GLP-1s and Lean Mass: Preserving Muscle and Strength During Rapid Weight Loss

GLP-1 medications support weight loss, but lean mass loss is a concern. Learn how to protect muscle, strength, and function during GLP-1 therapy.

The scale is moving fast, clothes are fitting better, and blood sugar numbers are improving. For many people using GLP-1 medications, weight loss can feel almost effortless at first. Yet beneath those encouraging changes, another question often emerges: is muscle being lost along with fat? For individuals focused on long-term …

Read More »

GLP-1s and Dermatologic Disease: From Psoriasis to Hidradenitis—Signal or Noise?

Dermatologist examining inflammatory skin lesions in a patient using GLP-1 therapy

A patient returns for follow-up after starting a GLP-1 receptor agonist and mentions something unexpected. Their blood glucose is improved, weight is down, and their psoriasis seems quieter. Another patient reports fewer hidradenitis flares. These anecdotes are becoming more common, raising a practical question for clinicians. Are GLP-1 therapies influencing …

Read More »

GLP-1s and Inflammatory Arthritis: What Early Signals Mean for Diabetes Care

GLP-1 injection pen next to inflamed knee joints illustrating the relationship between GLP-1 therapy and inflammatory arthritis in diabetes care

A patient with type 2 diabetes finally achieves better glycemic control on a GLP-1 receptor agonist. Weight is coming down, A1C is improving, and cardiovascular risk looks more manageable. Then an unexpected comment appears at a follow-up visit. Their joints feel better. For clinicians, moments like this raise an important …

Read More »

GLP-1s and Hypertension: Can Incretins Help Bring Blood Pressure to Goal?

GLP-1 injection pen next to blood pressure monitor showing controlled systolic and diastolic readings

GLP-1–based therapies have quickly become a cornerstone of modern diabetes care. While most clinicians think of these agents for glucose lowering and weight loss, growing evidence suggests they may also support better blood pressure control. For patients living with diabetes and hypertension, that overlap raises an important question. Can GLP-1 …

Read More »

Beyond Coverage: How GLP‑1s, Tech, and AI Are Reshaping Diabetes Equity in 2026

Diverse healthcare professionals and patients interacting with diabetes technology, symbolizing equitable access in 2026.

What happens when breakthrough treatments only reach the few who can afford or access them? That’s the growing dilemma in diabetes care. As GLP‑1 medications, digital tools, and AI reshape how we treat this chronic disease, the risk is clear: innovation could deepen inequality if we don’t act intentionally. Equity …

Read More »